Colorectal Cancer

Encouraging phase II trial results for radiolabeled humanized CEA antibody

Published in Cancer Weekly, April 2nd, 2002

Immunomedics, Inc., (IMMU) reported the publication of an article on clinical trial results with its radiolabeled, humanized antibody against carcinoembryonic antigen (CEA) in the February 15, 2002, supplement issue to the journal Cancer, a publication of the American Cancer Society.

This publication reported phase-II results of 30 colorectal cancer patients given the I-131-labeled humanized CEA antibody. Two sets of patients were studied, 21 with measurable metastatic colorectal cancer, and 9 who had their metastases completely resected prior to therapy (adjuvant group). Both groups received a single dose of the product, whereas 5 patients with documented...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2002-04-02)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry